Table 1.
Characteristic | Cases | Controls |
---|---|---|
No. of persons | 624 (100) | 1,246 (100) |
Cohort | ||
Alpha-Tocopherol, Beta-Carotene Study (ATBC) | 59 (9.5) | 117 (9.4) |
Cancer Prevention Study II (CPS-II) | 67 (10.7) | 136 (10.9) |
Health Professionals Follow-up Study (HPFS) | 28 (4.5) | 55 (4.4) |
Melbourne Collaborative Cohort Study (MCCS) | 52 (8.3) | 106 (8.5) |
Nurses’ Health Study (NHS) | 48 (7.7) | 90 (7.2) |
PLCO Cancer Screening Triala | 174 (27.9) | 348 (27.9) |
Women’s Health Initiative (WHI) | 196 (31.4) | 394 (31.6) |
Mean age at blood draw, years (SD) | 63.9 (7.0) | 63.9 (7.0) |
Sex | ||
Female | 355 (56.9) | 708 (56.8) |
Male | 269 (43.1) | 538 (43.2) |
Race | ||
White | 568 (91.2) | 1,138 (91.4) |
Black | 35 (5.6) | 68 (5.5) |
Other | 20 (3.2) | 39 (3.1) |
Mean BMI at blood draw, kg/m2 (SD) | 27.4 (5.0) | 27.2 (4.9) |
Type of blood sample | ||
EDTA plasma | 288 (46.2) | 579 (46.5) |
Heparin plasma | 274 (43.9) | 544 (43.7) |
Serum | 62 (9.9) | 123 (9.9) |
Time from blood draw to diagnosis | ||
< 6 years | 282 (45.2) | |
≥ 6 years | 342 (54.8) | |
Median biomarker concentration (IQR)b | ||
Total adiponectin, μg/mL | 11.5 (8.0-16.5)c | 12.8 (8.6-17.8) |
High-molecular-weight (HMW) adiponectin, μg/mL | 6.6 (4.3-10.1)c | 7.4 (4.7-10.8) |
Reported as frequency (%) unless otherwise noted
Analyzed separately in a previous investigation (13)
Reported as cohort- and sex-corrected analyte levels. Differences between cases and controls were also observed for uncorrected total and HMW adiponectin levels (P ≤ 0.005).
P ≤ 0.002 for cases vs. controls, Wilcoxon rank-sum test